OpenCareby Vivonco
Search/
Talk to us Review a case
Menu
Skip to content
No. 36 · Friday, November 13, 2026

antibody-drug conjugate izalontamab brengitecan improves survival in advanced food pipe cancer

  1. antibody-drug conjugate izalontamab brengitecan improves survival in advanced food pipe cancer
  2. Targeted drugs show activity against metastatic eye melanoma
  3. Perioperative camrelizumab plus chemotherapy improved outcomes in head and neck cancer
  4. Immunotherapy plus chemotherapy improved event-free survival in pancreatic cancer
  5. Cancer society updates prostate cancer screening advice
  6. Survey found gaps in lymphoma care across Latin America
  7. Children’s cancer survival reached 90% in 2017, but gaps remain
Read this first · Phase III trial · food pipe cancer

antibody-drug conjugate izalontamab brengitecan improves survival in advanced food pipe cancer

In a China-based trial of 497 people with recurrent or metastatic food pipe cancer after first-line treatment, people lived 9.79 months with antibody-drug conjugate izalontamab brengitecan versus 7.20 months with chemotherapy. Severe treatment-related side effects were more common with the antibody-drug conjugate.

“These findings support izalontamab brengitecan as a new second-line treatment for this population in China.”

Why it matters. People whose advanced food pipe cancer grows after first treatment may have another option that helped them live longer. Results from a large final-stage trial like this decide approvals.

JAMA, 12 Nov 2026 · Phase III human clinical trial | 704 patients Worth sharing · Share on X · Email a friend
Phase II trial · melanoma, a skin cancer

Targeted drugs show activity against metastatic eye melanoma

In a phase II trial, 44 people with untreated metastatic eye melanoma received the targeted drugs darovasertib and crizotinib. The tumors shrank in 34.1% of patients.

Why it matters. People with metastatic eye melanoma may have another targeted treatment option. A larger trial usually comes before approval.

The ASCO Post, 12 Nov 2026 · Phase II human clinical trial Worth sharing · Share on X · Email a friend
Phase II trial · head and neck cancer

Perioperative camrelizumab plus chemotherapy improved outcomes in head and neck cancer

In a phase 2 trial, 125 people with operable, locally advanced head and neck cancer received surgery-based treatment, with or without immunotherapy camrelizumab plus chemotherapy before surgery and camrelizumab afterward. At two years, 77.8% in the added-treatment group were event-free, compared with 46.1% in the control group.

Why it matters. People with operable, locally advanced head and neck cancer may have more time without cancer-related events with treatment before and after surgery. A larger trial usually comes before approval.

JAMA Oncology, 12 Nov 2026 · Phase II human clinical trial | 125 patients Worth sharing · Share on X · Email a friend
Phase II trial · pancreatic cancer

Immunotherapy plus chemotherapy improved event-free survival in pancreatic cancer

In a phase II trial, 392 people with borderline resectable or locally advanced pancreatic cancer received chemotherapy with or without the immunotherapy toripalimab. Time before an event was 11.1 months with the combination and 9.6 months with chemotherapy alone.

Why it matters. People with borderline resectable pancreatic cancer may have more time before an event when immunotherapy is added to chemotherapy. A larger trial usually comes before approval.

The ASCO Post, 12 Nov 2026 · Phase II human clinical trial | 392 patients Worth sharing · Share on X · Email a friend
Guideline · prostate cancer

Cancer society updates prostate cancer screening advice

The American Cancer Society recommends a prostate-specific antigen test every 2 years for average-risk men aged 50 to 69, and annual testing from age 45 for Black men and those with a strong family history. The guideline says screening reduces prostate cancer deaths and advanced diagnoses.

Why it matters. Men at higher risk may start screening earlier, while follow-up tests can help avoid unnecessary treatment. This is official guidance for doctors.

The ASCO Post, 12 Nov 2026 · Clinical practice guideline | 333,830 men
Research · lymphoma

Survey found gaps in lymphoma care across Latin America

A survey of cancer centers in Latin America found limited access to advanced tests and treatments for lymphoma. Commercial CAR-T therapy was available at 5% of centers.

“Our findings highlight striking disparities between guideline-recommended lymphoma care and real-world institutional capacity across LATAM, underscoring the importance of collaborative efforts in building capacity and advocating for equitable access.”

Why it matters. People with lymphoma in Latin America could benefit if centers gain better access to advanced tests and treatments. It studied patient records rather than testing a treatment.

JCO Global Oncology, 12 Nov 2026 · Human observational study
Research · children's cancer

Children’s cancer survival reached 90% in 2017, but gaps remain

Researchers reviewed records for children diagnosed with cancer in the United States from 1975 to 2022. Five-year survival rose from 60% in 1975 to 90% in 2017, but disparities by race and ethnicity persisted.

“Our findings, however, also point to where children and families still need us to do better.” Researchers looked at survival trends for children and adolescents with cancer in the United States between 1975 and 2022 to update outcome statistics and highlight disparities in trends to help guide future research.”

Why it matters. More children with cancer may live longer, though survival gains have not reached all racial and ethnic groups equally. It studied patient records rather than testing a treatment.

The ASCO Post, 12 Nov 2026 · Human observational study | 152,275 children

Deals and stopped trials

India

New trials

Worth watching